■ 学術雑誌
|
原著
|
|
1.
|
Kobayashi S, Nagano H, Tomokuni A, Gotoh K, Sakai D, Hatano E, Seo S, Terajima H, Uchida Y, Ajiki T, Satake H, Kamei K, Tohyama T, Hirose T, Ikai I, Morita S, Ioka T; Kansai Hepato-Biliary Oncology (KHBO) Group.：
A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group.
Ann Surg
270
(2)
：230
-237
, 2019
|
|
2.
|
Tanioka H, Nagasaka T, Uno F, Inoue M, Okita H, Katata Y, Kanzaki H, Kuramochi
H, Satake H, Shindo Y, Doi A, Nasu J, Yamashita H, Yamaguchi Y：
The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY).
BMC cancer
19
(1)
：941
, 2019
|
|
3.
|
Yuki S, Shinozaki K, Kashiwada T, Kusumoto T, Iwatsuki M, Satake H, Kobayashi K, Esaki T, Nakashima Y, Kawanaka H, Emi Y, Komatsu Y, Shimokawa M, Makiyama A, Saeki H, Oki E, Baba H, Mori M：
Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B.
Cancer chemotherapy and pharmacology
85
(1)
：217
-223
, 2020
|
|
4.
|
Ooki A, Morita S, Iwamoto S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M,
Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Suto T, Hashiguchi Y,
Yabuno T, Sakamoto J, Tsuji A, Ando M, Yamaguchi K：
Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.
Cancer medicine
9
(24)
：9419
-9430
, 2020
|
|
5.
|
Suzuki T, Sukawa Y, Imamura CK, Masuishi T, Satake H, Kumekawa Y, Funakoshi S, Kotaka M, Horie Y, Kawai S, Okuda H, Terazawa T, Kondoh C, Kato K, Yoshimura K, Ishikawa H, Hamamoto Y, Boku N, Takaishi H, Kanai T：
A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial).
Clinical colorectal cancer
19
(1)
：13
-21.e3
, 2020
|
|
6.
|
Munemoto Y, Nakamura M, Takahashi M, Kotaka M, Kuroda H, Kato T, Minagawa N,
Noura S, Fukunaga M, Kuramochi H, Touyama T, Takahashi T, Miwa K, Satake H,
Kurosawa S, Miura T, Mishima H, Sakamoto J, Oba K, Nagata N：
SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer.
European journal of cancer
119
：158
-167
, 2019
|
|
7.
|
Ogata M, Hatachi Y, Ogata T, Satake H, Imai Y, Yasui H：
Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation: A Case Report.
Internal medicine
58
(7)
：1029
-1032
, 2019
|
|
8.
|
Tanioka H, Honda M, Tanaka C, Morita Y, Ishibashi K, Kato T, Matsuda C, Kataoka M, Satake H, Munemoto Y, Kobayashi K, Takahashi M, Nakata K, Sakamoto J, Oba K, Mishima H：
Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treatedmetastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety.
International journal of clinical oncology
24
(7)
：836
-841
, 2019
|
|
症例報告
|
|
1.
|
齋藤智和, 林透, 駒木幹正, 中原浩, 船ケ山まゆみ, 中原真由美, 柴田伸弘, 長沼康子, 前田資雄：
男性乳腺原発の腺様囊胞癌の１例.
日本内分泌・甲状腺外科学会雑誌
36
(2)
：118
-122
, 2019
|
|
2.
|
Ogata M, Satake H, Ogata T, Hatachi Y, Hara S, Hirota S, Yasui H：
Reduction and Escalation in the Dose of Sunitinib Were Adequately Effective against Gastrointestinal Stromal Tumor of the Small Intestine.
Internal medicine (Tokyo, Japan)
58
(22)
：3243
-3246
, 2019
|
|
その他
|
|
1.
|
柴田 伸弘：
【おさらい!「がん」の基本 がん関連処方に備える、患者さんを支える】要点整理!がんノート(No.2) 乳がん.
Rp.+
19
(1)
：32
-37
, 2020
|
|
2.
|
柴田 伸弘：
【おさらい!「がん」の基本 がん関連処方に備える、患者さんを支える】がんを叩け!がん治療の方針とくすり 局所療法と全身療法.
Rp.+
19
(1)
：56
-61
, 2020
|
|
3.
|
柴田 伸弘：
【おさらい!「がん」の基本 がん関連処方に備える、患者さんを支える】がんを叩け!がん治療の方針とくすり 治癒を目指すのか延命を目指すのか.
Rp.+
19
(1)
：62
-66
, 2020
|
|
4.
|
Miki A, Satake H, Watanabe T, Tanaka N, Hirata K, Shimozaki K, Tanioka H, Matsuura M, Kyogoku T, Tatsumi M, Matoba K, Oka Y, Adachi S, Yasui H, Kotaka M, Kato T, Tsuji A：
Primary results of multicenter phase II study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PII).
Annals of oncology
30
(S5)
：786p
, 2019
|
|
5.
|
Ogata M, Satake H, Ama Y, Hirabatake M, Ogata T, Yasui H, Hashida T：
Safety and effectiveness of direct oral anticoagulants for venous thromboembolism in patients with active cancer: a retrospective study.
Annals of oncology
30
(Suppl 4)
：iv45
, 2019
|
|
6.
|
Sunakawa Y, Nakamura M, Ishizaki M, Kataoka M, Satake H, Kitazono M, Yanagisawa H, Kawamoto Y, Kuramochi H, Ohori H, Nakamura M, Takahashi K, Maeda F, Komeno C, Takeuchi M, Fujii M, Yoshino T, Ichikawa W, Tsuji A：
RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies n patients with metastatic colorectal cancer (mCRC).
Annals of oncology
30
(Suppl.4)
：114
, 2019
|
|
7.
|
Tanioka H, Nagasaka T, Uno F, Inoue M, Okita H, Katata Y, Kanzaki H, Kuramochi H, Satake H, Shindo Y, Doi A, Nasu J, Yamashita H, Yamaguchi Y：
Relationship between peripheral neuropathy and effectiveness in second-line chemotherapy for unresectable advanced gastric cancer: a prospective, observational, multicenter study protocol.
Annals of oncology
30
(Suppl.4)
：31
, 2019
|
|
8.
|
Masuishi, T; Moriwaki, T; Fukuoka, S; Takashima, A; Kumekawa, Y;
Kajiwara, T; Yamazaki, K; Esaki, T; Makiyama, A; Denda, T; Satake, H;
Suto, T; Sugimoto, N; Katsumata, K; Ishikawa, T; Kashiwada, T; Oki, E;
Komatsu, Y; Yoshimura, K; Shimada, Y：
Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
Journal of clinical oncology
37
(15)
：S3560
, 2019
|
|
■ 学会発表
|
国際学会及び海外の学会
|
|
1.
|
Kotaka M, Ogata M, Yasui H, Satake H：
Clinical features of Japanese patients with detailed RAS/BRAF mutant colorectal cancer.
ASCO GI,
SF、USA,
2020/01
|
|
2.
|
Sunakawa Y, Nakamura M, Ishizaki M, Kataoka M, Satake H, Kitazono M, Yanagisawa H, Kawamoto Y, Kuramochi H, Ohori H, Nakamura M, Maeda F, Komeno C, Takeuchi M, Fujii M, Yoshino T, Ichikawa W, Tsuji A：
RAS status in circulating-tumor DNA (ctDNA) and outcomes during rechallenge treatments with anti-EGFR antibodies in metastatic colorectal cancer (mCRC).
ASCO GI,
SF, USA,
2020/01
|
|
3.
|
◎ Kondo Masato, Satake Hironaga, Mizumoto Motoko, Miki Akira, Watanabe Takanori, Tanaka Norimitsu, Hirata Kenro, Tanioka Hiroaki, Okita Yoshihiro, Kyogoku Takahisa, Tatsumi Mitsutoshi, Matoba Koreatsu, Adachi Shinichi, Kaihara Satoshi, Yasui Hisateru, Tsuji Akihito：
Multicenter phase II study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PII).
ASCO GI,
SF, USA,
2020/01
|
|
4.
|
◎Katsuya Ohta, Takeshi Kato, Masahiro Goto, Tetsuji Terazawa, Shingo Noura, Hironaga Satake, Yoshinori Kagawa, Hisato Kawakami, Hiroko Hasegawa, Kazuhiro Yanagihara, Tatsushi Shingai, Ken Nakata, Masahito Kotaka, Masayuki Hiraki, Ken Konishi, Shiro Nakae, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, Taroh Satoh：
Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable,
RAS wild type colorectal cancer : OGSG 1602.
ASCO GI,
SF, USA,
2020/01
|
|
5.
|
◎Kumanishi R, Mitani S, Kadowaki S, Matsushima T, Ogata T, Takahashi N, Ogata M, Satake H, Narita Y, Masuishi T, Bando H, Yasui H, Hara H, Muro K：
Efficacy and safety of nivolumab and irinotecan as third-line chemotherapy for advanced gastric cancer
: A multi-institutional retrospective study.
ASCO GI,
SF, USA,
2020/01
|
|
6.
|
◎Masato Nakamura, Hironaga Satake, Koji Oba, Masahito Kotaka, Yoshinori Kagawa, Hisateru Yasui, Takanori Watanabe, Toshihiko Matsumoto, Takayuki Kii, Tetsuji Terazawa, Akitaka Makiyama, Nao Takano, Mitsuru Yokota, Yoshihiro Okita, Koreatsu Matoba, Hiroko Hasegawa, Akihito Tsuji, Naoki Nagata, Junichi Sakamoto, Takeshi Kato：
Final results of multicenter phase Ib/ II study of biweekly Trifluridine/tipiracil with bevacizumab combination for patients with mCRC refractory to standard therapies (BiTS study).
ASCO GI,
SF, USA,
2020/01
|
|
7.
|
◎Tsuji Akihito, Takayuki Yoshino, Takeharu Yamanaka, Hideaki Bando, Hironaga Satake, Kentaro Yamazaki, Hiroya Taniguchi, Eiji Oki, Masahito Kotaka, Koji Oba, Yoshinori Miyata, Kei Muro, Yoshito Komatsu, Hideo Baba, Takeshi Kato：
Study protocol of non-infusional triplet combination 1st line Treatment of CAPOXIRI plus Bevacizumab versus FOLFOXIRI plus Bevacizumab for mCRC, Multicenter Randomised Phase II study (QUATTRO-II).
ASCO GI,
SF, USA,
2020/01
|
|
8.
|
◎Miki A, Satake H, Watanabe T, Tanaka N, Hirata K, Shimozaki K, Tanioka H,
Matsuura M, Kyogoku T, Tatsumi M, Matoba K, Oka Y, Adachi S, Yasui H, Kotaka M, Kato T, Tsuji A：
Primary results of multicenter phase II study of neoadjuvant chemotherapy with S-1 and
oxaliplatin for locally advanced gastric cancer (Neo G-SOX PII).
ESMO,
Barcelona, Spain,
2019/09
|
|
9.
|
◎Hiroaki Tanioka, Takeshi Nagasaka, Futoshi Uno, Masafumi Inoue, Hiroyuki Okita, Yosuke Katata,Hiromitsu Kanzaki, Hidekazu Kuramochi, Hironaga Satake, Yoshiaki Shindo, Akira Doi, Jyunichiro Nasu, Haruhiro Yamashita, Yoshiyuki Yamaguchi：
Relationship between peripheral neuropathy and effectiveness in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol.
ESMO WCGC,
Barcelona, Spain,
2019/07
|
|
10.
|
◎Ogata M, Ama Y, Ogata T, Hirabatake M, Yasui H, Hashida T, Satake H：
Safety and effectiveness of direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) in patients with active cancer: a retrospective study.
ESMO WCGC,
Barcelona, Spain,
2019/07
|
|
11.
|
◎Yu Sunakawa, Masato Nakamura, Masahiro Ishizaki, Masato Kataoka, Hironaga Satake, Masaki Kitazono, Hideyuki Yanagisawa,Yasuyuki Kawamoto, Hidekazu Kuramochi, Hisatsugu Ohori, Michio Nakamura, Keita Takahashi, Fumiyo Maeda, Chihiro Komeno,Masahiro Takeuchi, Masashi Fujii, Takayuki Yoshino, Wataru Ichikawa, and Akihito Tsuji：
RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC).
ESMO WCGC,
Barcelona, Spain,
2019/07
|
|
12.
|
◎T. Ogata, H. Satake, M. Ogata, H. Yasui：
Diagnosis and outcomes of outpatients receiving chemotherapy who visited the emergency room: A retrospective study of 734 cases at a tertiary referral center.
ASCO,
シカゴ, USA,
2019/05
|
|
13.
|
◎Toshiki Masuishi, Toshikazu Moriwaki, Shota Fukuoka, Atsuo Takashima, Yosuke Kumekawa, Takeshi Kajiwara, Kentaro Yamazaki, Taito Esaki, Akitaka Makiyama, Tadamichi Denda,
Hironaga Satake, Takeshi Suto, Naotoshi Sugimoto, Kenji Katsumata, Toshiaki Ishikawa, Tomomi Kashiwada, Eiji Oki, Yoshito Komatsu, Kenichi Yoshimura, Yasuhiro Shimada：
Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil
in refractory metastatic colorectal cancer.
ASCO,
シカゴ, USA,
2019/05
|
|
14.
|
◎Y. Sunakawa, .., H. Satake, ..et al.：
Clinical verification of circulating cell-free RNA test as novel biomarker for pre-treatment predictor and quantitative monitoring of treatment response in metastatic colorectal cancer (mCRC): a biomarker study of the DEEPER trial.
ASCO,
シカゴ, USA,
2019/05
|
|
全国規模の学会
|
|
1.
|
柴田伸弘：
がん薬物療法に際して腫瘍内科医が行う有害事象評価と鑑別診断-薬剤師に期待する監察のポイント-
シンポジウム51：新しい時代を担う薬剤師の副作用マネジメントを考える～抗がん治療において患者を視るスキル～.
第29回日本医療薬学会年会,
福岡,
2019/11
|
|
2.
|
◎Akihito Tsuji, Yu Sunakawa, Masato Nakamura, Masahiro Ishizaki, Masato Kataoka, Hironaga Satake, Masaki Kitazono, Hideyuki Yanagisawa, Yasuyuki Kawamoto, Hidekazu Kuramochi, Hisatsugu Ohori, Michio Nakamura, Masahiro Takeuchi, Masashi Fujii, Takayuki Yoshino, and Wataru Ichikawa：
RAS mutations in circulating-tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC).
第57回 日本癌治療学会学術集会,
福岡,
2019/10
|
|
3.
|
◎H. Satake, T. Fujisawa, S. Sakagami, M. Shimizu, H. Iwai：
Predictive analysis for advanced head and neck cancer
treated with nivolumab.
第57回 日本癌治療学会学術集会,
福岡,
2019/10
|
|
4.
|
Toshiki Masuishi, Toshikazu Moriwaki, Shota Fukuoka, Atsuo Takashima, Yosuke Kumekawa, Takeshi Kajiwara, Kentaro Yamazaki, Taito Esaki, Akitaka Makiyama, Tadamichi Denda, Hironaga Satake, Takeshi Suto, Naotoshi Sugimoto, Kenji Katsumata, Toshiaki Ishikawa, Tomomi Kashiwada, Eiji Oki, Yoshito Komatsu, Kenichi Yoshimura, Yasuhiro Shimada：
Predictive factors for early mortality after regorafenib or trifluridine/tipiracil initiation in colorectal cancer.
第17回 日本臨床腫瘍学会学術集会,
京都,
2019/07
|
|
5.
|
◎M. Nakamura, E. Shinozaki, H. Osawa, Y. Ohhara, Y. Shindo, M. Shiozawa, H. Uetake, H. Matsumoto, N. Ureshino, H. Satake, T. Kobayashi, T. Suto, S. Kitano, Y. Ohashi, K. Uemura, K. Yamaguchi：
Phase II Study of Cetuximab Rechallenge in Patients with RAS Wild-Type metastatic Colorectal Cancer: E-Rechallenge Trial.
第17回 日本臨床腫瘍学会学術集会,
京都,
2019/07
|
|
6.
|
◎Masahito Kotaka, Hironaga Satake, Takatsugu Ogata, Misato Ogata, Hisateru Yasui：
Update data of multicenter analysis of the reintroducing oxaliplatin in relapsed CRC patients treated with prior oxaliplatin-based adjuvant chemotherapy.
第17回 日本臨床腫瘍学会学術集会,
福岡,
2019/07
|
|
7.
|
◎Masato Nakamura, Yu Sunakawa, Hiroyuki Okuyama, Masato Matsuura, Yuji Negoro, Taichi Yabuno, Takao Takahashi, Takao Tamura, Nobumichi Takeuchi, Hironaga Satake, Yuji Miyamoto, Masato Kataoka, Manabu Shiozawa, Akitaka Makiyama, Kazuma Kobayashi, Yutaro Kubota, Takashi Sekikawa, Masahiro Takeuchi, Wataru Ichikawa and Masashi Fujii：
Update on JACCRO CC-11 trial of 1st-line modified-FOLFOXIRI plus bevacizumab for RAS mutant metastatic colorectal cancer.
第17回 日本臨床腫瘍学会学術集会,
京都,
2019/07
|
|
8.
|
◎Ogata M, Satake H, Ama Y, Hirabatake M, Ogata T, Yasui H, Hashida T：
The safety and effectiveness of edoxaban, rivaroxaban and apixaban for venous thromboembolism in active cancer patients: a retrospective study.
第17回 日本臨床腫瘍学会学術集会,
京都,
2019/07
|
|
9.
|
◎Sunakawa Yu, Ichikawa Wataru, Hagiwara Ken, Tsuda Masahiro, Takagane Akinori, Yasui Hisateru, Satake Hironaga, Denda Tadamichi,Segawa Yoshihiko, Tanioka Hiroaki, Kotaka Masahito,Kochi Mitsugu,Watanabe Takanori, Nakamura Masato, Tsuji Akihito, Tani Satoshi, Negoro Yuji, Tobimatsu Kazutoshi, Takeuchi Masahiro, Fujii Masashi：
Update on phase II trial of cetuximab plus S–1/oxaliplatin (SOX) for metastatic colorectal cancer (mCRC): JACCRO CC-06.
第17回 日本臨床腫瘍学会学術集会,
京都,
2019/07
|
|
10.
|
◎Tsumura H, .. Satake H, et al.：
Phase II trial of GEMOX for the advanced pancreatic cancer with family/personal history of HBOC related cancer (FABRIC study).
第17回 日本臨床腫瘍学会学術集会,
京都,
2019/07
|
|
11.
|
◎崔諭司, 豊田昌徳, 飛松和俊, 佐竹悠良, 安井久晃, 石川瑶子, 金原史朗, 小山泰司, 藤島佳未, 今村善宣, 船越洋平, 清田尚臣, 外山博近, 児玉裕三, 南博信：
Phase I study of Gemcitabine / Nab-paclitaxel / S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial).
第17回 日本臨床腫瘍学会学術集会,
京都,
2019/07
|
|
12.
|
谷岡 洋亮, 永坂 岳司, 宇野 太, 井上 雅文, 大北 仁裕, 堅田 洋佑, 神崎 洋光, 倉持 英和, 佐竹 悠良, 進藤 吉 明, 土井 顕, 那須 淳一郎, 山下 晴弘, 山口 佳之：
切除不能進行・再発胃癌患者の二次化学療法中における末梢神経障害と薬剤効果を検討する前向き多施設共同観察研究.
第17回 日本臨床腫瘍学会学術集会,
京都,
2019/07
|
|
13.
|
◎玉嶋恵美, 山﨑文和, 佐竹悠良, 植田郁子, 神戸直智, 久米典子, 寺井沙也加, 松田智子, 松山美江, 岡本祐之：
当科で経験した化学療法による皮膚障害66例の検討.
第118回日本皮膚科学会総会,
名古屋市,
2019/06
|
|
14.
|
◎角田貴代美、中村聡明、朴正旭、蓮尾英明、佐竹悠良、武川英樹、姉帯優介、由井緑、河野由美子、谷川昇：
放射線診断画像全例介入による骨関連事象回避のためのシステム構築.
第24回日本緩和医療学会学術大会,
神奈川,
2019/06
|
|
15.
|
◎Kohei Shitara, Eric Van Cutsem, Yung-Jue Bang, Charles Fuchs, Lucjan Wyrwicz, Keun-Wook Lee, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, Hugo Castro, Wasat Mansoor, Maria Ignez Braghiroli, Eray Goekkurt, Joseph Chao, Zev A. Wainberg, Hironaga Satake, Kensei Yamaguchi, Takaki Yoshikawa, Shi Rong Han, Uma Kher, Sukrut Shah, Soonmo Peter Kang, Josep Tabernero：
KEYNOTE-062: Pembrolizumab ± Chemotherapy Versus Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer.
第17回 日本臨床腫瘍学会学術集会,
京都,
2019/07
|
|
その他
|
|
1.
|
◎平井千恵、矢内洋次、杉江知治、蓮尾英明、佐久間博子、松森恵理：
Mohs軟膏処置および術前化学療法によって手術可能となった局所進行乳癌の1例.
第41回日本癌局所療法研究会,
岡山,
2019/06
|
|
